Nevertheless, the facts that TLR9 agonists increases IgM secretion from cancer cells and that this increase can be abolished by chloroquine and MyD88 knockdown with siRNA suggest that the expression and secretion of cancer-derived IgM is mediated through the TLR9-MyD88 pathway. This evidence concerns the gene MYD88 and cancer.